Amanta Healthcare Limited has announced its financial results for the quarter and year ended March 31, 2026. The company reported a total revenue of 7,699.49 lakhs for the fourth quarter, reflecting a quarterly increase of 3.37% compared to the previous quarter (7,448.74 lakhs) and a yearly increase of 6.84% compared to the corresponding quarter of the previous year (7,206.28 lakhs). The net profit for the quarter stood at 511.01 lakhs, showing a quarterly growth of 12.84% from the previous quarter (452.85 lakhs), but a decrease of 11.97% compared to the corresponding quarter of the previous year (580.47 lakhs).

Amanta Healthcare Limited, established in 1994 and headquartered in Ahmedabad, Gujarat, is a prominent pharmaceutical company specializing in the development and manufacture of sterile liquid products. The company utilizes advanced Blow-Fill-Seal (BFS) and Injection Stretch Blow Moulding (ISBM) technologies to produce a wide range of parenteral solutions, including IV fluids, diluents, ophthalmic, and respiratory care products. In September 2025, the company successfully completed its Initial Public Offering (IPO), raising 126 Crores to fund capital expenditure for new manufacturing lines at its Hariyala, Gujarat facility. As of early 2026, the company continues to focus on capacity expansion and strengthening its domestic and global market presence through its SteriPort and other branded product lines.